Erectile dysfunction gel receives FDA green light

An over-the-counter topical treatment for men with erectile dysfunction on May 12 was authorized by the FDA for marketing. Futura Medical’s Eroxon gel can now be marketed as a de novo medical device.

Advertisement

The drug already can be purchased in Belgium as of 2021 and in the U.K. as of 2022.

CNN noted in a June 12 report that the drug’s product notes said “the gel comes in a single-dose tube and should be applied to the head of the penis for 15 seconds before sex. Marketing materials for the product claim that it can help users get an erection within 10 minutes of application.”

Currently, Futura does not have a partner to market Eroxon in the United States, but “some financial analysts predict that the product could launch in 2025,” the CNN report said.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.